<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277730</url>
  </required_header>
  <id_info>
    <org_study_id>SHF/CTG047/2012</org_study_id>
    <nct_id>NCT02277730</nct_id>
  </id_info>
  <brief_title>A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability</brief_title>
  <acronym>DIVA</acronym>
  <official_title>A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability to Improve Perioperative Outcome During Spinal Anaesthesia for Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KK Women's and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KK Women's and Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypotension occurs commonly during spinal anaesthesia for caesarean section with maternal and
      fetal adverse effects. The investigators developed a double-vasopressor automated system
      incorporating continuous non-invasive haemodynamic monitoring using NexfinTM with a two-step
      algorithm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotension occurs commonly during spinal anaesthesia for caesarean section with maternal and
      fetal adverse effects. We developed a double-vasopressor automated system incorporating
      continuous non-invasive haemodynamic monitoring using Nexfin cardiac output monitor with a
      two-step algorithm. The system delivered phenylephrine 25 mcg or ephedrine 2 mg (if heart
      rate&lt;60 beats.min-1) every 30 seconds when systolic blood pressure was between 90-100% of
      baseline. The system delivered phenylephrine 50 mcg or ephedrine 4 mg (if heart rate&lt;60
      beats.min-1) every 30 seconds when systolic blood pressure was &lt;90% of baseline.

      A randomised controlled trial will be done to compare with manual bolus technique. With the
      manual bolus technique, phenylephrine 50mcg or ephedrine 4mg (if heart rate&lt;60 beats.min-1)
      every 60 seconds when systolic blood pressure was between 90-100% of baseline. The system
      delivered phenylephrine 100mcg or ephedrine 8mg (if heart rate&lt;60 beats.min-1) every 60
      seconds when systolic blood pressure was &lt;90% of baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hypotension</measure>
    <time_frame>1 day</time_frame>
    <description>Systolic blood pressure less than 80% of baseline systolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypertension</measure>
    <time_frame>1 day</time_frame>
    <description>Systolic blood pressure more than 120% of baseline systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting</measure>
    <time_frame>1 day</time_frame>
    <description>Nausea and vomiting during Caesarean section</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Hypotension</condition>
  <arm_group>
    <arm_group_label>vasopressor delivery automated system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>manual vasopressor delivery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vasopressor delivery automated system</intervention_name>
    <description>vasopressor delivery using phenylephrine and ephedrine</description>
    <arm_group_label>vasopressor delivery automated system</arm_group_label>
    <other_name>vasopressor delivery technique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phenylephrine</intervention_name>
    <arm_group_label>vasopressor delivery automated system</arm_group_label>
    <arm_group_label>manual vasopressor delivery</arm_group_label>
    <other_name>vasopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ephedrine</intervention_name>
    <arm_group_label>vasopressor delivery automated system</arm_group_label>
    <arm_group_label>manual vasopressor delivery</arm_group_label>
    <other_name>vasopressor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>manual vasopressor delivery</intervention_name>
    <arm_group_label>manual vasopressor delivery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 21-45 years old,

          -  weight 40-90 kg,

          -  height 145-170 cm

        Exclusion Criteria:

          -  contraindications to spinal anaesthesia,

          -  allergy to drugs used in the study, and

          -  those with uncontrolled medical conditions such as hypertension, diabetes mellitus,
             and cardiovascular disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ban L Sng, FANZCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>KK Women's and Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypotension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

